$515 Million is the total value of BVF INC/IL's 24 reported holdings in Q2 2013. The portfolio turnover from Q1 2013 to Q2 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LGND | New | LIGAND PHARMACEUTICALS INC | $135,523,000 | – | 3,621,665 | +100.0% | 26.30% | – |
| CCXI | New | CHEMOCENTRYX INC | $71,078,000 | – | 5,026,766 | +100.0% | 13.79% | – |
| IRWD | New | IRONWOOD PHARMACEUTICALS INC | $52,263,000 | – | 5,252,561 | +100.0% | 10.14% | – |
| ARRY | New | ARRAY BIOPHARMA INC | $50,539,000 | – | 11,131,858 | +100.0% | 9.81% | – |
| New | EXELIXIS INCnote 4.250% 08/15/2019 | $39,411,000 | – | 40,735,000 | +100.0% | 7.65% | – | |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $32,501,000 | – | 9,730,697 | +100.0% | 6.31% | – |
| TRGT | New | TARGACEPT INC | $26,353,000 | – | 6,171,669 | +100.0% | 5.11% | – |
| CYTK | New | CYTOKINETICS INC | $19,888,000 | – | 1,718,905 | +100.0% | 3.86% | – |
| ONTY | New | ONCOTHYREON INC | $12,626,000 | – | 8,093,278 | +100.0% | 2.45% | – |
| New | ARRAY BIOPHARMA INCnote 3.000% 06/01/2020 | $11,423,000 | – | 12,000,000 | +100.0% | 2.22% | – | |
| EXEL | New | EXELIXIS INC | $11,360,000 | – | 2,502,256 | +100.0% | 2.20% | – |
| QLTI | New | QLT INC | $10,405,000 | – | 2,370,263 | +100.0% | 2.02% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $7,513,000 | – | 305,786 | +100.0% | 1.46% | – |
| RCPT | New | RECEPTOS INC | $6,365,000 | – | 320,000 | +100.0% | 1.24% | – |
| ARQL | New | ARQULE INC | $6,107,000 | – | 2,632,432 | +100.0% | 1.18% | – |
| PTIE | New | PAIN THERAPEUTICS INC | $5,210,000 | – | 2,357,327 | +100.0% | 1.01% | – |
| AVNR | New | AVANIR PHARMACEUTICALS INCcl a new | $4,628,000 | – | 1,006,053 | +100.0% | 0.90% | – |
| PTN | New | PALATIN TECHNOLOGIES INC | $3,120,000 | – | 5,200,000 | +100.0% | 0.60% | – |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $2,718,000 | – | 153,500 | +100.0% | 0.53% | – |
| RGLS | New | REGULUS THERAPEUTICS INC | $2,614,000 | – | 266,445 | +100.0% | 0.51% | – |
| ANTH | New | ANTHERA PHARMACEUTICALS INC | $2,073,000 | – | 4,477,000 | +100.0% | 0.40% | – |
| FLML | New | FLAMEL TECHNOLOGIES SAsponsored adr | $931,000 | – | 151,406 | +100.0% | 0.18% | – |
| TSPT | New | TRANSCEPT PHARMACEUTICALS INC | $453,000 | – | 150,000 | +100.0% | 0.09% | – |
| GNVC | New | GENVEC INC | $180,000 | – | 486,100 | +100.0% | 0.04% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.